. Erratum: Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O6-Methylguan J Clin Oncol 2024 Oct 10:JCO2402040. doi: 10.1200/JCO-24-02040.
PMID: 39388656